You are here

Temasek unit pares stakes in S Korean pharma firms for as much as S$1.36b

Celltrion develops and manufactures biosimilars, which are lower-cost laboratory-generated clones of higher-priced biological medicines.


TEMASEK Holdings' unit Ion Investments on Wednesday said it is paring its stakes in two South Korean pharmaceutical companies but will remain a substantial shareholder in both.

Earlier on Tuesday, IFR reported that Ion is selling part of its stakes in Celltrion Inc, and

Market voices on:

Powered by GET.comGetCom